An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Camurus AB
- 电话号码:+46 46 286 57 30
- 邮箱:medicalinfo@camurus.com
学习地点
-
-
-
Aachen、德国、52074
- 招聘中
- Universitaetsklinikum Aachen
-
Leipzig、德国、04103
- 招聘中
- Universitaetsklinikum Leipzig
-
Magdeburg、德国、39110
- 招聘中
- Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
-
München、德国、81667
- 尚未招聘
- Medicover Neuroendokrinologie MVZ
-
Münster、德国、48149
- 尚未招聘
- Universitätsklinikum Münster
-
Würzburg、德国、97080
- 招聘中
- Universitätsklinikum Würzburg
-
-
-
-
-
Leeds、英国、LS9 7TF
- 尚未招聘
- St James's University Hospital - Leeds Teaching Hospitals NHS Trust
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study will enroll patients with acromegaly who are considered for treatment with octreotide subcutaneous depot and patients with acromegaly who have already initiated octreotide subcutaneous depot treatment. The study will be conducted in Germany, the UK, and the US.
描述
Inclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for acromegaly
Exclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly
- Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
大体时间:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
大体时间:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with IGF-1 ≤1×ULN over time.
大体时间:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in GH levels over time.
大体时间:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with GH levels <1.0 μg/L over time.
大体时间:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
大体时间:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
大体时间:From enrollment to the end of treatment at 2 years
|
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
大体时间:From enrollment to the end of treatment at 2 years
|
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
大体时间:From enrollment to the end of treatment at 2 years
|
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
大体时间:From enrollment to the end of treatment at 2 years
|
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.